CA-TELESIGN
TeleSign , a leader in authentication and communication services, a wholly-owned subsidiary of BICS, today announced a new partnership with Proximus , the largest telecommunications company in Belgium. This partnership will provide TeleSign’s fraud risk product portfolio to provide regional and international companies with a presence in Belgium.
As the mobile identity ecosystem continues to rapidly evolve globally, it is more important than ever that businesses ensure the strongest authentication and verification measures to secure end-user accounts and prevent fraud, especially in the financial sector. According to PwC , almost two-thirds (65 percent) of companies in Belgium experienced economic crime in the last two years, compared to under half (49 percent) globally. Fraud such as account take over (ATO) through SIM swap and porting attacks can be significantly expensive to both end users and businesses. With the strength of Proximus’ insights and TeleSign’s expertise, this partnership will aid businesses in complying with the new EU Payment Services Directive, PSD2 and its two core use cases – Know Your Customer (KYC) and Strong Customer Authentication (SCA) .
This new partnership with Proximus highlights the increasing importance of Mobile Identity and the key role played by Mobile Operators in digital transformation. It represents a new opportunity to Mobile Operators worldwide to participate in a Global Mobile Identity ecosystem and improve the security of their end users online.
“TeleSign helps its customers globally to protect and prevent fraudulent activity for the end user and businesses,” said Pierre Demarche, VP of Products at TeleSign. “Telesign has existing partnerships with other Mobile Operators in multiple geographies, and keeps expanding its partnership with Mobile Operators worldwide, so we have a deep understanding of how Mobile Identity can be leveraged to provide end-to-end security experience. This protection not only works to prevent costly fraud, but also enhances the user experience.”
“As the leading telecommunications company in Belgium, quality of data and security services to our customers is top of mind, and so is being able to develop services that will protect our customers from fraudulent activity,” said Jeroen Degadt, Director Carrier and Wholesale at Proximus. “Partnering with TeleSign, a global neutral aggregator, was the clear choice. With access to TeleSign’s fraud risk product portfolio, we will be able to provide increased security and assurance for our customers across the country.”
TeleSign is a trusted partner to 21 of the top 25 global websites and mobile applications, enabling them to securely and effectively communicate with billions of end-user accounts. TeleSign offers telecommunications companies like Proximus the ability to secure their customer base and protect users from fraud and identity theft.
For more information about how TeleSign can support mobile operators, please visit https://info.telesign.com/Suppliers.html .
About TeleSign
TeleSign connects and protects online experiences with sophisticated customer identity and engagement solutions. Through APIs that deliver user verification, data insights, and communications we solve today’s unique customer challenges by bridging your business to the complex world of global telecommunications. TeleSign is a subsidiary of BICS, Brussels. BICS is a leading international communications enabler, one of the key global voice carriers and the leading provider of mobile data services worldwide with Proximus as its majority shareholder.
Learn more at www.telesign.com and follow us on Twitter at @TeleSign .
About Proximus
The Proximus Group is a telecommunication and ICT company operating in the Belgian and international markets, serving residential customers, businesses, and public institutions. Proximus aims to open up a world of digital opportunities so that people can live better and work smarter. The company is at the heart of the digital revolution, delivering communication and entertainment experiences for residential consumers and enabling digital transformation for enterprises. Through its best-quality integrated fixed and mobile networks, Proximus provides access anywhere and anytime to digital services and easy-to-use solutions, and is a gateway to multimedia content. Proximus is a pioneer in ICT innovation, with integrated solutions that have a positive impact on society and the environment, based on Internet of Things (IoT), Data analytics, cloudification, and security. With 13,385 employees, all striving to offer customers a superior experience, the Group realized an underlying Group revenue of EUR 5,804 million end-2018.
Proximus (Euronext Brussels: PROX) is also active in Luxembourg through its affiliate Proximus Luxembourg and in the Netherlands through Telindus Netherlands. BICS is a leading international communications enabler, one of the key global voice carriers, and the leading provider of mobile data services worldwide.
For more information, visit www.proximus.com and www.proximus.be .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191022005356/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom